Predictive value of [ 99m Tc]Tc-MAA SPECT/CT personalised dosimetry in 90 Y radioembolization of…

StudyEuropean journal of nuclear medicine and molecular imaging· Aug 2026

Predictive value of [ 99m Tc]Tc-MAA SPECT/CT personalised dosimetry in 90 Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study.

Grace Keane, J Chalaye, B Guiu … M G E H Lam

TheranosticsStudyQ1IF 5.8

Predictive Tc-MAA dosimetry strongly correlates with actual post-treatment radiation dose delivered.

Predictive value of [ 99m Tc]Tc-MAA SPECT/CT personalised dosimetry in 90 Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study.

Grace Keane … M G E H Lam

European journal of nuclear medicine and molecular imaging · Aug 2026 · Q1 in Radiology

Purpose

The DOSISPHERE-01 study demonstrated a survival benefit for patients treated with 90 Y radioembolization using personalised [ 99m Tc]Tc-MAA guided versus standard dosimetry guided treatment.

Methods

All DOSISPHERE-01 patients with both pre-treatment [ 99m Tc]Tc-MAA SPECT/CT and post-treatment 90 Y imaging were eligible.

Results

predicted and actual delivered radiation doses to liver and tumor track closely

241Gy

Pre-treatment index le

229Gy

Post-treatment index l

More results

Corresponding metrics were significantly different using count-threshold segmentation (p < 0.05).

“

Conclusion · 1 of 2

90 Y absorbed dose outcomes in the DOSISPHERE-01 study corresponded closely with [ 99m Tc]Tc-MAA predictive dosimetry, confirming the validity of [ 99m Tc]Tc-MAA for dosimetry-based treatment planning in this clinical scenario.

Conclusion · 2 of 2

Agreement was maximised using anatomic segmentation.

Predictive value of [ 99m Tc]Tc-MAA SPECT/CT personalised dosimetry in 90 Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study.

Predictive value of [ 99m Tc]Tc-MAA SPECT/CT personalised dosimetry in 90 Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study.

Related papers